What are the domestically approved indications for Avatrombopag/Suxin?

Avatrombopag/Suxin (Avatrombopag) has been approved by the Food and Drug Administration in China, has clear indications, and provides precise treatment options for different types of thrombocytopenia. Its main indications include adult patients with chronic liver disease-associated thrombocytopenia and chronic primary immune thrombocytopenia (ITP).

In patients with thrombocytopenia associated with chronic liver disease, avatrombopag is indicated primarily for adult patients requiring elective diagnostic procedures or surgery. Such patients have a higher risk of bleeding due to thrombocytopenia, and avatrombopag stimulates platelet production to bring the platelet count to a safe range before surgery or operations, thereby reducing the probability of surgical bleeding. It should be noted that this drug is not used to restore platelets to normal levels, but to adjust the platelet count according to clinical needs to ensure safe operation.

In adult patients with chronic primary immune thrombocytopenia (ITP), avatrombopag is suitable for patients who have had poor response to previous treatments such as glucocorticoids and immunoglobulins. Such patients often have insufficient platelet production or rapid destruction of platelets. Using avatrombopag can increase platelet counts and reduce or prevent bleeding events. The drug is only used in patients with increased risk of bleeding due to thrombocytopenia and clinical conditions, emphasizing individualized treatment and risk assessment to ensure safe medication.

In actual clinical use, the oral administration of avatrombopag facilitates long-term management of patients. At the same time, its efficacy is relatively controllable, and the rate of platelet increase is moderate to avoid the risk of thrombosis caused by too rapid increase. Doctors will adjust the dose based on the patient's platelet baseline, bleeding risk, and concomitant diseases, and conduct regular hematology monitoring during treatment to ensure that platelet levels are stable and safe.

Reference materials:https://go.drugbank.com/drugs/DB11995